ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
By Elana Gotkine HealthDay Reporter
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.
Dima Bechenati, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined whether tirzepatide efficacy differs between postmenopausal women using MHT (+MHT) versus those not using MHT (−MHT) in the treatment of overweight and obesity. Propensity score matching was used in a real-world study, with each +MHT participant matched to two −MHT controls based on age, body mass index, age at menopause, menopause type, and diabetes status.
A total of 120 women were included in the analysis after propensity score matching: 40 in the +MHT group and 80 in the −MHT group. The median follow-up duration was 18 months for both groups. The researchers found that at the last follow-up, significantly greater total body weight loss was achieved by the +MHT versus the −MHT group (17 versus 14 percent). In addition, the proportion of women who achieved ≥20 percent total body weight loss by the last follow-up was higher in the +MHT versus the −MHT group (45 versus 18 percent).
"These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women," coauthor Regina Castaneda, M.D., also from the Mayo Clinic, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 -- For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs)...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Many Indicators of Anger Expression Decrease With Age in Women
THURSDAY, July 10, 2025 -- Aging is significantly related to anger in women, with most indicators of anger expression decreasing with age, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.